ArticleBMJ open2021
Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data.
Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.Journal of environmental and public health · 2023Pooled it
- Michelolide Enhances the Anticancer Efficacy of Radiation by Downregulating PD-L1 Protein Levels in Tumor Cells.International journal of molecular sciences · 2026Article
- A different perspective on the cancer stem cell theory.Medical oncology (Northwood, London, England) · 2026Review
- Factors Associated With Risk Stratification and Overall Survival of Black South African Men With Non-Metastatic Prostate Cancer.Cancer medicine · 2026Article
- Metal-based triazoles as a medical marvel of the modern era: a comprehensive review.RSC advances · 2026Review
- Implementing Remote Radiotherapy Planning to Increase Patient Flow at a Johannesburg Academic Hospital, South Africa: Protocol for a Prospective Feasibility Study.JMIR research protocols · 2025Article
- Does orthodontic postgraduate education influence the choice of orthodontic treatment?Frontiers in dental medicine · 2025Article
- Efficiency of evidence-based collaborative nursing on complications, negative emotions and quality of live in radical prostatectomy.American journal of translational research · 2025Article
- Fusion feature-based hybrid methods for diagnosing oral squamous cell carcinoma in histopathological images.Frontiers in oncology · 2025Article
- Treatment of cancer patients by generalizing a Fermatean normal vague set with aggregation operators.Heliyon · 2024Article
- Prognostic determinants in cancer survival: a multidimensional evaluation of clinical and genetic factors across 10 cancer types in the participants of Genomics England's 100,000 Genomes Project.Discover oncology · 2024Article
- Article
- Efficiency of C-reactive protein in prognosis evaluation of prostate cancer: a systematic review and meta-analysis.Translational cancer research · 2021Article
- New approaches and procedures for cancer treatment: Current perspectives.SAGE open medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo confirm the association of previously reported prognostic factors with future progression of localised prostate cancer using primary care data and identify new potential prognostic factors for further assessment in prognostic model development and validation.
designRetrospective cohort study, employing Cox proportional hazards regression controlling for age, prostate specific antigen (PSA), and Gleason score, was stratified by diagnostic stage.
settingPrimary care in England.
participantsMales with localised prostate cancer diagnosedbetween 01/01/1987 and 31/12/2016 within the Clinical Practice ResearchDatalink database, with linked data from the National Cancer Registration andAnalysis Service and Office for National Statistics. PRIMARY AND SECONDARY OUTCOMES: Primary outcome measure was prostate cancer mortality. Secondary outcome measures were all-cause mortality and commencing systemic therapy. Up-staging after diagnosis was not used as a secondary outcome owing to significant missing data.
results10 901 men (mean age 74.38±9.03 years) with localised prostate cancer were followed up for a mean of 14.12 (±6.36) years. 2331 (21.38%) men underwent systemic therapy and 3450 (31.65%) died, including 1250 (11.47%) from prostate cancer. Factors associated with an increased risk of prostate cancer mortality included age; high PSA; current or ex-smoker; ischaemic heart disease; high C reactive protein; high ferritin; low haemoglobin; high blood glucose and low albumin.
conclusionsThis study identified several new potential prognostic factors for prostate cancer progression, as well as confirming some known prognostic factors, in an independent primary care data set. Further research is needed to develop and validate a prognostic model for prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.